Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry
Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation < 92% and an elevated C reactive protein (AUC = 0.87; Hosmer-Lemeshow test, p > 0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-ORhydroxychloroquine 0.88; 95% CI 0.81-0.91, p = 0.005; adjusted-ORantiviral 0.94; 95% CI 0.87-1.01; p = 0.115). COVID-19 produces important mortality, mostly in patients with comorbidities with respiratory symptoms. Hydroxychloroquine could be associated with survival benefit, but this data need to be confirmed with further trials. Trial Registration: NCT04334291/EUPAS34399.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Internal and emergency medicine - 16(2021), 4 vom: 09. Juni, Seite 957-966 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 16.07.2021 Date Revised 18.02.2022 published: Print-Electronic ClinicalTrials.gov: NCT04334291 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11739-020-02543-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31733509X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31733509X | ||
| 003 | DE-627 | ||
| 005 | 20231225163041.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11739-020-02543-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1057.xml |
| 035 | |a (DE-627)NLM31733509X | ||
| 035 | |a (NLM)33165755 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Núñez-Gil, Iván J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.07.2021 | ||
| 500 | |a Date Revised 18.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04334291 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation < 92% and an elevated C reactive protein (AUC = 0.87; Hosmer-Lemeshow test, p > 0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-ORhydroxychloroquine 0.88; 95% CI 0.81-0.91, p = 0.005; adjusted-ORantiviral 0.94; 95% CI 0.87-1.01; p = 0.115). COVID-19 produces important mortality, mostly in patients with comorbidities with respiratory symptoms. Hydroxychloroquine could be associated with survival benefit, but this data need to be confirmed with further trials. Trial Registration: NCT04334291/EUPAS34399 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Registry | |
| 650 | 4 | |a Score | |
| 700 | 1 | |a Fernández-Pérez, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Estrada, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Becerra-Muñoz, Víctor M |e verfasserin |4 aut | |
| 700 | 1 | |a El-Battrawy, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Uribarri, Aitor |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Rozas, Inmaculada |e verfasserin |4 aut | |
| 700 | 1 | |a Feltes, Gisela |e verfasserin |4 aut | |
| 700 | 1 | |a Viana-Llamas, María C |e verfasserin |4 aut | |
| 700 | 1 | |a Trabattoni, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a López-País, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Pepe, Martino |e verfasserin |4 aut | |
| 700 | 1 | |a Romero, Rodolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Castro-Mejía, Alex F |e verfasserin |4 aut | |
| 700 | 1 | |a Cerrato, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Astrua, Thamar Capel |e verfasserin |4 aut | |
| 700 | 1 | |a D'Ascenzo, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Fabregat-Andres, Oscar |e verfasserin |4 aut | |
| 700 | 1 | |a Moreu, José |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Signes-Costa, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Marín, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Buosenso, Danilo |e verfasserin |4 aut | |
| 700 | 1 | |a Bardají, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Raposeiras-Roubín, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Elola, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Molino, Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Doblas, Juan J |e verfasserin |4 aut | |
| 700 | 1 | |a Abumayyaleh, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Aparisi, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Molina, María |e verfasserin |4 aut | |
| 700 | 1 | |a Guerri, Asunción |e verfasserin |4 aut | |
| 700 | 1 | |a Arroyo-Espliguero, Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Assanelli, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Mapelli, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a García-Acuña, José M |e verfasserin |4 aut | |
| 700 | 1 | |a Brindicci, Gaetano |e verfasserin |4 aut | |
| 700 | 1 | |a Manzone, Edoardo |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega-Armas, María E |e verfasserin |4 aut | |
| 700 | 1 | |a Bianco, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Trung, Chinh Pham |e verfasserin |4 aut | |
| 700 | 1 | |a Núñez, María José |e verfasserin |4 aut | |
| 700 | 1 | |a Castellanos-Lluch, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a García-Vázquez, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Cabello-Clotet, Noemí |e verfasserin |4 aut | |
| 700 | 1 | |a Jamhour-Chelh, Karim |e verfasserin |4 aut | |
| 700 | 1 | |a Tellez, María J |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Ortiz, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Macaya, Carlos |e verfasserin |4 aut | |
| 700 | 0 | |a HOPE COVID-19 Investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal and emergency medicine |d 2006 |g 16(2021), 4 vom: 09. Juni, Seite 957-966 |w (DE-627)NLM165086432 |x 1828-0447 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2021 |g number:4 |g day:09 |g month:06 |g pages:957-966 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11739-020-02543-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2021 |e 4 |b 09 |c 06 |h 957-966 | ||